GuruFocus·Jun 25, 2026
Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders?Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 25, 2026
Apogee Therapeutics, Inc.(APGE)Earnings, Financials & Key Ratios
APGE•NASDAQ
$133.50
Price updated Jul 6, 2026
AboutApogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.Show more
- Revenue$0
- EBITDA-$284M-31.1%
- Net Income-$256M-40.5%
- EPS (Diluted)-4.22-27.9%
- ROE-31.57%+5.0%
APGE Price & Volume
Apogee Therapeutics, Inc. (APGE) stock price & volume — 10-year historical chart
Loading chart...
Escalating Clinical Costs Drive Persistent Operational Deficits
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial execution dependency
Key Thesis Takeaways
- Apogee Therapeutics operates as a pre-revenue clinical-stage biotechnology firm, where the primary value driver remains the successful advancement of its pipeline through capital-intensive development phases.
- The company's reliance on external equity financing to sustain operations is evidenced by a deepening retained earnings deficit of $635.9 million as of 2026Q1.
- Investors should monitor the sustainability of this model, as the current trajectory of rising R&D expenditures and stock-based compensation may necessitate further dilutive capital raises to maintain clinical momentum.
Verdict Logic
the company's reliance on external funding to cover an accelerating quarterly free cash flow burn of $55.6 million presents significant long-term dilution risks for shareholders.
APGE Growth Metrics
Apogee Therapeutics, Inc. (APGE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-33.7%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-19.28%
Return on Capital
10 Years-32.84%
5 Years-32.84%
3 Years-36.57%
Last Year-34.94%
APGE Recent Earnings
Apogee Therapeutics, Inc. (APGE) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$1.06+0.9%
$1.07
Rev
—
—
Q2 2026
Mar 2, 2026Metric
Actual
Est
EPS
$1.03+1.9%
$1.05
Rev
—
—
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$1.11+0.9%
$1.12
Rev
—
—
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$1.13-9.7%
$1.03
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $1.06vs $1.07+0.9% | — |
| Q2 2026 | Mar 2, 2026 | $1.03vs $1.05+1.9% | — |
| Q4 2025 | Nov 10, 2025 | $1.11vs $1.12+0.9% | — |
| Q3 2025 | Aug 11, 2025 | $1.13vs $1.03-9.7% | — |
Based on last 12 quarters of dataView full earnings history →
Latest APGE News
Recent stock market news and headlines for Apogee Therapeutics, Inc. (APGE)
ETF Trends·Jun 25, 2026
Biotech ETF Index Surges 10% After RebalanceAfter a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underlying index gained 10.01% in six trading days following its June 18 semi-annual rebalance.
Fool - Investing News·Jun 25, 2026
Is AbbVie a Buy After Its Purchase of Apogee?The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 billion?
Peers Comparison
Key metrics vs top competitors for Apogee Therapeutics, Inc. (APGE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $133.50 | $8.26B | -31.64 | — | — | -31.57% | — | |
| $649.81 | $67.52B | 15.67 | 0.99% | 29.65% | 14.32% | — | |
| $115.07 | $6.73B | -28.27 | -79.35% | -1027.25% | -55.42% | — | |
| $3.96 | $1.77B | -2.75 | 26.92% | -844.46% | -54.32% | — | |
| $26.07 | $3.26B | -200.54 | 91.34% | -0.57% | -1.41% | — | |
| $21.53 | $2.22B | -20.70 | 20.6% | -67.85% | -23.43% | — |
Compare APGE vs Peers
Apogee Therapeutics, Inc. (APGE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
APGE SEC Filings & Documents
Apogee Therapeutics, Inc. (APGE) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 11, 2026·SEC
Material company update
Apr 24, 2026·SEC
Material company update
Mar 25, 2026·SEC
10-K Annual Reports
310-Q Quarterly Reports
6Get notified when APGE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
APGE Frequently Asked Questions
Apogee Therapeutics, Inc. (APGE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is APGE profitable?
Apogee Therapeutics, Inc. (APGE) reported a net loss of $274.6M for fiscal year 2025.
Dividend & Returns
What is APGE's return on equity?
Apogee Therapeutics, Inc. (APGE) has a return on equity (ROE) of -31.6%. Negative ROE indicates the company is unprofitable.
What is Apogee Therapeutics, Inc.'s free cash flow?
Apogee Therapeutics, Inc. (APGE) had negative free cash flow of $235.4M in fiscal year 2025, likely due to heavy capital investments.